Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
M Pletscher, R Plessow, K Eichler… - Swiss medical …, 2013 - digitalcollection.zhaw.ch
Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
T Davidson, M Husberg, M Janzon… - European heart …, 2013 - academic.oup.com
Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …
events such as ischaemic stroke, and patients are therefore recommended to be treated with …
[HTML][HTML] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective
J Chevalier, O Delaitre, F Hammès… - Archives of …, 2014 - Elsevier
Background Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …
Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
LK Langkilde, M Bergholdt Asmussen… - Journal of Medical …, 2012 - Taylor & Francis
Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium
H Wouters, V Thijs, L Annemans - Journal of medical economics, 2013 - Taylor & Francis
Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …
[HTML][HTML] Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
LS Miguel, E Rocha, J Ferreira - Revista Portuguesa de Cardiologia …, 2013 - Elsevier
Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain
JR González-Juanatey, J Álvarez-Sabin… - Revista Española de …, 2012 - Elsevier
INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack
Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …
[PDF][PDF] Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece
GK Andrikopoulos, V Fragoulakis… - Hellenic J …, 2013 - researchgate.net
Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis
A Ali, C Bailey, AH Abdelhafiz - Age and ageing, 2012 - academic.oup.com
Background: cost of anticoagulation with dabigatran is largely based on estimation of
complication rates derived from clinical trials. Objective: to investigate cost of anticoagulation …
complication rates derived from clinical trials. Objective: to investigate cost of anticoagulation …